Novartis AG (NYSE:NVS) reportedly faced a legal setback as it failed to convince a federal court to block MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto. On Monday, U.S. District Judge Richard Andrews in Delaware ruled that Novartis’ likelihood of winning its patent-infringement lawsuit was too low to justify stopping MSN Pharmaceuticals’ launch. Also Read: Novartis Sues to Block Maryland’s New Drug Discount Law. Despite this ruling, the judge temporarily suspended MSN Pharmaceuticals’ sales while Novartis appealed to the U.S. Court of Appeals for the Federal Circuit. Entresto is Novartis’ top-selling drug. In the ...